All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Gastric cancer (GC) is one of the most common cancers worldwide and a leading cause of cancer-related death \[[@pone.0136447.ref001]\]. The initiation and development of GC is a multistep process influenced by genetic and environmental factors. Studies have indicated that exogenous environmental factors including *Helicobacter pylori* (HP) infection, diet habits, smoking, alcohol drinking, and economic factors contribute to gastric carcinogenesis \[[@pone.0136447.ref002]\]. Under similar environmental conditions, individuals with different genetic background suffer different risks of cancer with diverse clinical outcomes. Until now, the interaction of genetic and environmental factors with gastric carcinogenesis has been largely unknown.

Polymorphisms are a class of genetic factors that participate in gastric carcinogenesis and determine inter-individual variations in GC risk. Genetic polymorphisms can weaken intrinsic protective mechanisms and increase the damage caused by environmental carcinogens. Carriers of susceptible genotypes are at a greater risk of developing cancer than those with resistant genotypes under similar conditions. Therefore, genetic factors play a crucial role in GC risk and clinical outcome.

The phosphoinositide 3-kinase (PI3K)/protein kinase B (PKB, AKT)/mammalian target of rapamycin (MTOR) pathway regulates various cellular functions including growth, proliferation, migration, and apoptosis. Tapia et al. reported that the PI3K/AKT/MTOR pathway is activated in GC and that most proteins (phosphorylated and unphosphorylated forms) studied so far in this pathway are overexpressed in tumor tissues \[[@pone.0136447.ref003]\]. MTOR is a key member of the PI3K/AKT/MTOR pathway and a core metabolic signaling molecule \[[@pone.0136447.ref004], [@pone.0136447.ref005]\]. Single nucleotide polymorphisms (SNPs) may affect MTOR expression and transcriptional activity, thereby altering protein function. So far, a total of 14 polymorphisms in this gene have been studied, of which three SNPs (rs2295080, rs1883965, and rs2536) have been most widely reported. The rs2295080 polymorphism in the promoter region is reported to reduce the risk of renal cell carcinoma \[[@pone.0136447.ref006]\], GC \[[@pone.0136447.ref007]\], and prostate cancer \[[@pone.0136447.ref008]\] by downregulating endogenous protein expression. The rs1883965 polymorphism has been associated with an increased risk of GC \[[@pone.0136447.ref009]\] and esophageal squamous cancer \[[@pone.0136447.ref010]\]. Moreover, rs2536 polymorphism is related to a significantly increased risk of prostate cancer \[[@pone.0136447.ref008]\]. In addition, the *MTOR* rs11121704 polymorphism is associated with worse clinical parameters (death, metastasis, and chemotherapy resistance) \[[@pone.0136447.ref011]\]. There are 45 exons in the *MTOR* gene, and the rs1064261 polymorphism is located in exon 18. The T→C variation is located at the boundary of exon 18 and intron 19, but its relation with disease is still unclear.

The *AKT* gene is critical for cell survival and encodes an important downstream effector of the PI3K/*AKT*/*MTOR* pathway that regulates key cellular functions including glucose metabolism and protein synthesis. *AKT*, alternatively known as *AKT1*, has five widely studied polymorphisms (rs3803300, rs1130214, rs2494732, rs2498804, and rs1130233); the first four have been linked to the risk or prognosis of nasopharyngeal carcinoma, oral squamous cell carcinoma, and non-small cell lung cancer. The rs1130233 polymorphism is located in exon 8 and the G→A variation is located at the boundary of exon 8 and intron 7. The *AKT*1 AA haplotype for both rs1130233 and rs2494732 is reported to confer an elevated risk of nasopharyngeal carcinoma \[[@pone.0136447.ref012]\]; the haplotype containing variant alleles of rs1130214 and rs3803300 polymorphisms significantly increases susceptibility to oral squamous cell carcinoma \[[@pone.0136447.ref013]\]. Carriers of the (GT+GG) genotype of *AKT*1 rs2498804 or the CT/TT genotype of *AKT*1 rs2494732 were found to have an increased risk of brain metastasis of non-small cell lung cancer \[[@pone.0136447.ref014]\]. *AKT*1 rs3803300, rs1130214, and rs2494732 have significant effects on survival in non-small cell lung cancer patients: patients with the rs3803300 G allele and rs1130214 G allele had shorter overall survival (OS) and disease-free survival (DFS) times \[[@pone.0136447.ref015]\].

Although variations in *MTOR* and *AKT* play important roles in gastric carcinogenesis, no study has investigated the relation of *AKT* polymorphism with GC risk and prognosis. In addition, the mechanistic link between *MTOR* rs1064261 and both cancer susceptibility and survival are unknown. To elucidate whether *MTOR* and *AKT* polymorphisms can serve as risk and/or prognostic markers for GC, we investigated *MTOR* rs1064261 and *AKT* rs1130233 polymorphisms in relation to GC risk and their interactions with *H*. *pylori* in a case--control study of 1842 subjects. In 205 individuals with sufficient data, clinicopathological parameters were analyzed to explore the association of these two polymorphisms with GC prognosis and thus identify new biomarkers for GC risk and prognosis.

Materials and Methods {#sec006}
=====================

Study design and study population {#sec007}
---------------------------------

The design of this study was approved by the Human Ethics Committee of the First Affiliated Hospital of China Medical University (Shenyang, China). Each participant provided written informed consent during an epidemiological investigation. The study design included two parts (polymorphism and protein level analyses) and associations between polymorphisms and disease risk and prognosis were investigated. In the GC risk analysis, the GC patients were from the First Affiliated Hospital of China Medical University which obtained surgery operation resection or gastroscopic diagnosis/treatment between 2004 and 2013. The AG patients and controls were recruited from a health check program in Zhuanghe, Liaoning Province, between 2002 and 2013. All diagnoses were based on gastroscopic and histopathological examinations.

In addition, GC cases were classified into intestinal type and diffuse type based on Lauren's classification \[[@pone.0136447.ref016], [@pone.0136447.ref017]\]; AG classification and staging were based on the new Sydney system \[[@pone.0136447.ref018], [@pone.0136447.ref019]\]. Control participants had normal stomach findings or gastritis only. The information about the smoking habit, alcohol consumption and family history were acquired by "face to face" questionnaire survey. The smokers and alcoholic drinks were defined as follow: if one smoked more than once per day and if this lasted more than 1 year, then this individual was defined as smokers, and this situation included current smokers and former smokers who had quit smoking for more than 1 year. Persons who did not satisfy this situation were defined as never smokers. If one consumed one bottle of beer or a fifth pound of liquor a day and if this situation lasted more than 1 year, then this person was considered drinkers. Individuals who did not fit this standard were defined as nondrinkers. Fasting venous blood was obtained from each participant and stored at −20°C as serum and clotted cells.

To further evaluate the relation of polymorphisms with clinicopathological parameters and survival of GC, we performed a prognostic analysis of GC patients for whom sufficient clinical data was available. Histology data were assessed according to Health Organization criteria and tumor--node--metastasis (TNM) staging of postoperative pathologic specimens was done according to 7th edition of the of the International Union Against Cancer (UICC)/American Joint Committee on Cancer (AJCC) (2010) criteria. Patients with distant metastasis before surgery, those who received radiotherapy or chemotherapy before surgery, and those with insufficient information for prognostic analysis were excluded. A sensitivity analysis was performed to test whether the excluded patients had effect to the survival analysis. Follow-up for all patients was completed in May 2014.

SNP genotyping {#sec008}
--------------

Genomic DNA was extracted from blood samples using the phenol--chloroform method \[[@pone.0136447.ref020]\] and diluted to working concentration of 50 ng/μl for *MTOR* rs1064261 T→C and *AKT* rs1130233 G→A genotyping. Samples were placed randomly in 384-well plates and analyzed in a blinded manner to disease status. Genotyping was performed using the Sequenom MassARRAY platform (Sequenom, San Diego, California, USA) according to the manufacturer's instructions. For quality control, 5% of samples underwent repeated genotyping; the results were 100% consistent.

H. pylori serology examination {#sec009}
------------------------------

Serology analysis to detect *H*. *pylori* infection was performed using ELISA (*H*. *pylori*-IgG ELISA kit, BIOHIT, Helsinki, Finland), as described previously \[[@pone.0136447.ref021]\]. A reading of \>34 enzyme immune units was regarded to indicate *H*. *pylori* positivity.

Detection of MTOR and AKT proteins in tissue {#sec010}
--------------------------------------------

Immunohistochemical analysis was used to determine the expression of total and phosphorylated MTOR and AKT (p-MTOR and p-AKT) proteins in 65 formalin-fixed, paraffin-embedded GC tissue samples. Tissue samples were cut into 4-μm-thick sections and mounted onto poly-[l-]{.smallcaps}lysine-coated glass slides. After citric acid antigen retrieval, primary antibody was incubated with tissue sections at 4°C overnight (dilution concentration: MTOR and p-MTOR 1:100, AKT 1:300, and p-AKT 1:50, all were purchased from Cell Signaling Technology). After three 5-min washes in phosphate buffer saline, tissue sections were incubated with biotinylated secondary antibody (Maixin, Fujian, China) and streptavidin--biotin peroxidase for 10 min each at 37°C. For negative controls, primary antibody was replaced with PBS buffer.

Statistical analysis {#sec011}
--------------------

Statistical analysis was performed using SPSS (version 18.0) statistical software (SPSS, Chicago, IL, USA). Hardy--Weinberg equilibrium (HWE) was first evaluated in healthy controls. Adjusted odds ratios and 95% confidence intervals (CIs) for the relation between both polymorphisms and disease risk were calculated by multivariable logistic regression, with adjustment for gender, age, and *H*. *pylori* infection status. In a stratified analysis, when stratified by age, the sex and *H*.*pylori* infection status were adjusted; when stratified by sex, the age and *H*.*pylori* infection status were adjusted; and when stratified by *H*.*pylori* infection status, the sex and age were adjusted. The likelihood ratio test was performed to assess the interaction effects of genotype and *H*. *pylori* on disease risk by comparing the model involving only the main effects of gender, age, *H*. *pylori* status, and genotype with the full model (also containing the interaction term of genotype with *H*. *pylori* status). Pearson's χ^2^ test was used to evaluate the relation of different genotypes with the clinicopathological parameters of GC. Fisher's exact method was used when the expected frequency was less than five. The Kaplan--Meier method was used to visualize OS by genotype group. The log-rank test was used to investigate differences in survival distributions. Univariable and multivariable Cox proportional hazards models were performed to calculate the crude or adjusted hazards ratios and 95% CIs for each genotype to estimate the effect on survival with or without adjustment for confounding factors. Logistic regression analysis was used to explore the effect of polymorphisms on protein expression adjusted by gender, age, and *H*. *pylori* status. Two-tailed *P* values of \<0.05 were considered statistically significant.

Results {#sec012}
=======

Baseline patient characteristics {#sec013}
--------------------------------

The demographic and clinical characteristics of the 1842 individuals involved in the risk analysis comprising 483 GC patients, 686 AG patients and 673 healthy controls are shown in [Table 1](#pone.0136447.t001){ref-type="table"}. Both SNPs were present in HWE; the genotype distribution is listed in [Table 2](#pone.0136447.t002){ref-type="table"}. The result of the sensitivity analysis was shown in [S1 Table](#pone.0136447.s001){ref-type="supplementary-material"}, which verified the excluded patients had no effect to the survival analysis. The demographic and clinical characteristics of the 205 GC patients involved in the survival analysis including age, sex, Borrmann classification, Lauren's classification, TNM stage, growth pattern, invasion depth, lymph node metastasis, smoking, drinking, family history, and *H*. *pylori* infection are shown in [Table 3](#pone.0136447.t003){ref-type="table"}.

10.1371/journal.pone.0136447.t001

###### The basic messages of the objects.

![](pone.0136447.t001){#pone.0136447.t001g}

  Variability                        Gastric mucosa status                                            
  ---------------------------------- ----------------------- ------------ ------------- ------------- -------------
  **For SNP study**                                                                                   
  N                                  673                     683          461           138           200
  Age                                ***P*\<0.001**                                                   
  Mean±SD                            52.93±9.90              55.03±9.20   58.95±11.24   60.54±10.56   58.21±12.50
  Median                             53                      56           58            59            58
  Range                              17--85                  16--82       26--87        31--84        26--87
  Gender                             ***P*\<0.001**                                                   
  Male                               342(50.8)               386(56.3)    316(68.0)     107(76.4)     125(61.9)
  Female                             331(49.2)               300(43.7)    149(32.0)     33(23.6)      77(38.1)
  *H*.*pylori*                       ***P\<*0.001**                                                   
  Positive                           146(21.8)               403(59.6)    249(52.1)     78(56.1)      105(50.2)
  Negative                           523(78.2)               273(40.4)    229(47.9)     61(43.9)      104(49.8)
  **For protein expression study**                                                                    
  N                                                                       65                          
  Age                                                                                                 
  Mean±SD                                                                 55.9±11.4                   
  Median                                                                  56                          
  Range                                                                   31--82                      
  Gender                                                                                              
  Male                                                                    42(64.6)                    
  Female                                                                  23(35.4)                    
  *H*.*pylori*                                                                                        
  Positive                                                                25(38.5)                    
  Negative                                                                40(61.5)                    

**Abbreviations:** CON, control; AG, atrophic gastritis; GC, gastric cancer; SD, standard deviation; N, number of the objects.

10.1371/journal.pone.0136447.t002

###### Association of mTOR rs1064261 and AKT rs1130233 polymorphisms with the risk of atrophic gastritis and gastric cancer.

![](pone.0136447.t002){#pone.0136447.t002g}

  Stratified     SNP                                                    Gastric mucosa status   AG vs. CON   GC vs. AG   GC vs. CON             GC vs. CON+AG                                                                                                
  -------------- ------------------------------------------------------ ----------------------- ------------ ----------- ---------------------- --------------- ---------------------- ----------- ---------------------- ----------- ---------------------- -----------
                 mTOR rs1064261[\*](#t002fn002){ref-type="table-fn"}                                                                                                                                                                                         
                 TT                                                     560(83.2)               584(85.1)    402(83.2)   1(Ref)                                 1(Ref)                             1(Ref)                             1(Ref)                 
                 TC                                                     107(15.9)               97(14.1)     76(15.7)    0.92(0.66--1.28)       0.626           1.22(0.87--1.71)       0.259       0.96(0.67--1.37)       0.804       1.12(0.83--1.51)       0.478
                 CC                                                     6(0.9)                  5(0.7)       5(1.0)      0.56(0.15--2.09)       0.391           1.78(0.50--6.36)       0.374       1.26(0.35--4.51)       0.722       1.38(0.46--4.15)       0.564
                 HWE                                                    0.724                                                                                                                                                                                
                 AKT rs1130233[\*](#t002fn002){ref-type="table-fn"}                                                                                                                                                                                          
                 GG                                                     144(21.5)               129(19.1)    89(18.5)    1(Ref)                                 1(Ref)                             1(Ref)                             1(Ref)                 
                 GA                                                     329(49.0)               362(53.5)    236(49.0)   1.21(0.89--1.64)       0.234           1.06(0.76--1.49)       0.719       1.14(0.80--1.62)       0.481       1.16(0.86--1.56)       0.347
                 AA                                                     198(29.5)               186(27.5)    157(32.6)   1.09(0.77--1.54)       0.637           1.26(0.88--1.82)       0.214       1.25(0.85--1.85)       0.252       1.31(0.95--1.82)       0.100
                 HWE                                                    0.737                                                                                                                                                                                
  Sex            mTOR rs1064261[^§^](#t002fn003){ref-type="table-fn"}                                                                                                                                                                                        
  Male           TT                                                     283(82.7)               336(87.0)    260(82.3)   1(Ref)                                 1(Ref)                             1(Ref)                             1(Ref)                 
                 TC                                                     55(16.1)                48(12.4)     54(17.1)    0.70(0.44--1.12)       0.138           **1.55(1.00--2.38)**   **0.049**   0.97(0.62--1.51)       0.880       1.29(0.89-.186)        0.184
                 CC                                                     4(1.2)                  2(0.5)       2(0.6)      0.28(0.04--1.94)       0.199           1.34(0.18--9.79)       0.775       0.73(0.12--4.30)       0.724       0.87(0.17--0.448)      0.863
  Sex            AKT rs1130233[^§^](#t002fn003){ref-type="table-fn"}                                                                                                                                                                                         
  Male           GG                                                     74(21.7)                84(22.0)     53(16.8)    1(Ref)                                 1(Ref)                             1(Ref)                             1(Ref)                 
                 GA                                                     170(49.9)               200(52.5)    154(48.7)   0.97(0.64--1.47)       0.891           1.32(0.87--2.00)       0.192       1.30(0.83--2.05)       0.255       1.33(0.91--1.94)       0.139
                 AA                                                     97(28.4)                97(25.5)     109(34.5)   0.88(0.55--1.42)       0.609           **1.76(1.12--2.77)**   **0.014**   **1.70(1.03--2.81)**   **0.039**   **1.71(1.14--2.57)**   **0.009**
  *H*.*pylori*   AKT rs1130233[^\#^](#t002fn004){ref-type="table-fn"}                                                                                                                                                                                        
  Negative       GG                                                     118(22.6)               43(15.9)     47(20.6)    1(Ref)                                 1(Ref)                             1(Ref)                             1(Ref)                 
                 GA                                                     246(47.2)               149(55.2)    105(46.1)   **1.69(1.12--2.54)**   **0.012**       0.72(0.43--1.19)       0.194       1.21(0.78--1.87)       0.400       1.02(0.67--1.53)       0.945
                 AA                                                     157(30.1)               78(28.9)     76(33.3)    1.39(0.89--2.18)       0.144           0.94(0.55--1.62)       0.830       1.29(0.81--2.05)       0.288       1.18(0.76--1.83)       0.470

**Note:**

\*using Logistic Regession adjusted by sex, age and *H*.*pylori* infection status.

^§^using Logistic Regession adjusted by age and *H*.*pylori* infection status.

^\#^using Logistic Regession adjusted by sex and age.

**Abbreviations:** SNP, single nucleotide polymorphism; CON, control; AG, atrophic gastritis; GC, gastric cancer; OR, odds ratio; CI, confidence interval; Ref, reference; HWE, Hardy-Weinberg Equilibrium in population.

10.1371/journal.pone.0136447.t003

###### Clinical features of gastric cancer patients.

![](pone.0136447.t003){#pone.0136447.t003g}

  Variables               GC patients   Death   MST                                           Log-rank               HR(95%CI)
  ----------------------- ------------- ------- --------------------------------------------- ---------------------- -------------------------
  Age                                                                                                                
  ≤50                     54(26.34)     20      55.31[^a^](#t003fn002){ref-type="table-fn"}                          1(Ref)
  \>50                    151(73.66)    47      62.23[^a^](#t003fn002){ref-type="table-fn"}   0.495                  0.83(0.49--1.41)
  Sex                                                                                                                
  Female                  63(30.73)     25      43.43[^a^](#t003fn002){ref-type="table-fn"}                          1(Ref)
  Male                    142(69.27)    42      64.93[^a^](#t003fn002){ref-type="table-fn"}   0.130                  0.66(0.42--1.20)
  Borrmann type                                                                                                      
  Borrmann I--II          76(37.07)     29      60.81[^a^](#t003fn002){ref-type="table-fn"}                          1(Ref)
  Borrmann III--IV        101(49.27)    37      44.0                                          0.632                  1.13(0.69--1.84)
  Lauren classification                                                                                              
  Intestinal              75(36.59)     18      64.55[^a^](#t003fn002){ref-type="table-fn"}                          1(Ref)
  Diffuse                 129(62.93)    49      57.88[^a^](#t003fn002){ref-type="table-fn"}   **0.036**              **1.78(1.04--3.06)**
  TNM stage                                                                                                          
  I--II                   120(58.54)    22      73.69[^a^](#t003fn002){ref-type="table-fn"}                          1(Ref)
  III--IV                 85(41.46)     45      31.0                                          **4.01×10** ^**−7**^   **3.76(2.25--6.27)**
  Growth pattern                                                                                                     
  Massive and Nested      70(34.15)     12      35.07[^a^](#t003fn002){ref-type="table-fn"}                          1(Ref)
  Diffused                64(31.22)     24      27.15[^a^](#t003fn002){ref-type="table-fn"}   **0.005**              **2.73(1.36--5.46)**
  Depth of invasion                                                                                                  
  T1+T2                   43(20.98)     1       37.63[^a^](#t003fn002){ref-type="table-fn"}                          1(Ref)
  T3+T4                   91(44.39)     35      28.74[^a^](#t003fn002){ref-type="table-fn"}   **0.003**              **20.15(2.76--147.11)**
  Lymphatic metastasis                                                                                               
  Negative                77(37.56)     11      71.77[^a^](#t003fn002){ref-type="table-fn"}                          1(Ref)
  Positive                128(62.44)    56      53.01[^a^](#t003fn002){ref-type="table-fn"}   **4.39×10** ^**−5**^   **3.86(2.02--7.36)**
  Smoking                                                                                                            
  Never Smoker            80(39.02)     21      31.79[^a^](#t003fn002){ref-type="table-fn"}                          1(Ref)
  Ever Smoker             54(26.34)     15      31.23[^a^](#t003fn002){ref-type="table-fn"}   0.795                  1.09(0.56--2.12)
  Alcohol drinking                                                                                                   
  Nondrinker              90(43.90)     24      31.59[^a^](#t003fn002){ref-type="table-fn"}                          1(Ref)
  Drinker                 44(21.46)     12      30.76[^a^](#t003fn002){ref-type="table-fn"}   0.909                  1.04(0.52--2.08)
  Family history                                                                                                     
  No                      107(52.20)    33      30.48[^a^](#t003fn002){ref-type="table-fn"}                          1(Ref)
  Yes                     27(13.17)     3       35.85[^a^](#t003fn002){ref-type="table-fn"}   0.052                  0.31(0.10--1.01)
  *H*. *pylori*-IgG                                                                                                  
  Negative                86(41.95)     29      60.74[^a^](#t003fn002){ref-type="table-fn"}                          1(Ref)
  Positive                117(57.07)    37      59.02[^a^](#t003fn002){ref-type="table-fn"}   0.743                  0.92(0.57--1.50)

**Note:**

^a^, mean survival time was provided when MST could not be calculated.

**Abbreviations:** MST, median survival time (months); HR, hazard rate; CI, confidence interval; GC, gastric cancer; N, number of patients; M, months.

Association of SNPs with GC and AG risk {#sec014}
---------------------------------------

Multivariable logistic regression was used to investigate the association of *MTOR* rs1064261and *AKT* rs1130233 with GC and AG risk. There was no significant difference of *MTOR* rs1064261 and *AKT* rs1130233 on the risk of CON→AG, AG→GC, CON→GC, or CON+AG→GC progression ([Table 2](#pone.0136447.t002){ref-type="table"}).

In the stratification analysis of males ([Table 2](#pone.0136447.t002){ref-type="table"}), carriers of the TC genotype of *MTOR* rs1064261 had a 1.55-fold increased risk of GC compared with AG (*P* = 0.049, 95% CI 1.00--2.38); the A allele of *AKT* rs1130233 conferred 1.32-fold, 1.29-fold, and 1.30-fold increases in AG→GC, CON→GC, and (CON+AG)→GC progression, respectively, over the G allele (*P* = 0.013, 95% CI 1.06--1.64; *P* = 0.038, 95% CI 1.01--1.64; and *P* = 0.008, 95% CI 1.07--1.58, [S2 Table](#pone.0136447.s002){ref-type="supplementary-material"}). In the *H*. *pylori*-negative group, the *AKT* rs1130233 GA genotype was associated with a 1.69-fold increased risk of AG compared with CON (*P* = 0.012, 95% CI 1.12--2.54, [Table 2](#pone.0136447.t002){ref-type="table"}). In addition, no significant association was found between these two polymorphisms and intestinal-type or diffuse-type GC in the overall and stratified analyses ([S3](#pone.0136447.s003){ref-type="supplementary-material"} and [S4](#pone.0136447.s004){ref-type="supplementary-material"} Tables).

We then performed an interaction analysis for *MTOR* rs1064261 and *AKT* rs1130233 with *H*. *pylori* infection. The results indicated that the *AKT* rs1130233 (GA+AA) genotype had a significant interaction with *H*. *pylori* infection in CON→AG and AG→GC progression (*P* = 0.013 and *P* = 0.049; [Table 4](#pone.0136447.t004){ref-type="table"}). However, no significant interaction of *MTOR* rs1064261 with *AKT* rs1130233 was observed for CON→AG→GC progression in the overall and stratified analyses ([S5 Table](#pone.0136447.s005){ref-type="supplementary-material"}). Additionally, there was no significant interaction between these two polymorphisms and *H*. *pylori* infection in CON→AG→GC progression ([Table 4](#pone.0136447.t004){ref-type="table"}).

10.1371/journal.pone.0136447.t004

###### The interaction of MTOR rs1064261 and AKT rs1130233 polymorphisms in the risk of atrophic gastritis and gastric cancer[\*](#t004fn002){ref-type="table-fn"}.

![](pone.0136447.t004){#pone.0136447.t004g}

  Genotypes                         AG vs. CON       GC vs. AG                               GC vs. CON                              GC vs. CON+AG                                                                                                     
  ---------------- ---------------- ---------------- --------------------------------------- --------------------------------------- --------------------------- --------------------------- ------------------ ------------------- ------------------ ------------------
                   MTOR rs1064261                                                                                                                                                                                                                      
                   TT               Controls/Cases   432/229                                 124/348                                 229/196                     348/202                     432/196            124/202             661/196            472/202
                                    OR(95%CI)        1(Ref)                                  5.33(4.10--6.91)                        1(Ref)                      0.68(0.53--0.89)            1(Ref)             3.64(2.74--4.83)    1(Ref)             1.46(1.16--1.84)
                   TC+CC            Controls/Cases   91/44                                   22/55                                   44/33                       55/47                       91/33              22/47               135/33             77/47
                                    OR(95%CI)        0.92(0.62--1.37)                        4.76(2.83--8.00)                        0.92(0.56--1.50)            1.00(0.65--1.56)            0.85(0.55--1.31)   4.78(2.79--8.18)    0.87(0.58--1.32)   2.08(1.39--3.11)
                                                     *P* ~interaction~ = 0.926               *P* ~interaction~ = 0.195               *P* ~interaction~ = 0.270   *P* ~interaction~ = 0.093                                                             
                   AKT rs1130233                                                                                                                                                                                                                       
                   GG               Controls/Cases   118/43                                  24/86                                   43/47                       86/41                       118/47             24/41               161/47             110/41
                                    OR(95%CI)        1(Ref)                                  9.83(5.55--17.41)                       1(Ref)                      0.43(0.24--0.76)            1(Ref)             4.23(2.27--7.87)    1(Ref)             1.26(0.76--2.08)
                   GA+AA            Controls/Cases   403/227                                 122/313                                 227/181                     313/208                     403/181            122/208             630/181            435/208
                                    OR(95%CI)        1.54(1.05--2.26)                        7.02(4.67--10.54)                       0.77(0.49--1.24)            0.64(0.41--1.02)            1.19(0.81--1.76)   4.52(2.99--6.85)    1.04(0.72--1.52)   1.73(1.19--2.53)
                                                     ***P*** ~**interaction**~ **= 0.013**   ***P*** ~**interaction**~ **= 0.049**   *P* ~interaction~ = 0.702   *P* ~interaction~ = 0.366                                                             
  MTOR rs1064261   AKT rs1130233                                                                                                                                                                                                                       
  TT               GG               Controls/Cases   35/92                                   75/20                                   5/8                         9/11                        42/92              32/20               42/127             *32/95*
                                    OR(95%CI)        1(Ref)                                  9.86(5.26--18.48)                       1(Ref)                      0.36(0.19--0.67)            1(Ref)             3.51(1.77--6.96)    1(Ref)             1.02(0.59--1.77)
  TT               GA+AA            Controls/Cases   192/339                                 269/104                                 28/153                      38/170                      153/339            170/104             153/531            170/373
                                    OR(95%CI)        1.48(0.97--2.27)                        6.77(4.32--10.63)                       0.71(0.43--1.18)            0.56(0.34--0.93)            1.05(0.69--1.61)   3.82(2.43--5.99)    0.93(0.62--1.39)   1.47(0.98--2.21)
  TC+CC            GG               Controls/Cases   8/26                                    11/4                                    8/35                        11/75                       5/26               9/4                 5/34               9/15
                                    OR(95%CI)        0.81(0.34--1.96)                        7.23(2.16--24.21)                       0.58(0.17--1.93)            0.67(0.24--1.86)            0.47(0.17--1.30)   4.84(1.38--17.04)   0.49(0.18--1.34)   1.78(0.70--4.52)
  TC+CC            GA+AA            Controls/Cases   35/64                                   44/18                                   35/192                      44/269                      28/64              38/18               28/99              38/62
                                    OR(95%CI)        1.44(0.82--2.53)                        6.43(3.28--12.59)                       0.74(0.38--1.45)            0.78(0.41--1.46)            1.06(0.59--1.90)   4.98(2.53--9.81)    0.95(0.54--1.65)   1.99(1.16--3.44)
                                                     *P* ~interaction~ = 0.809               *P* ~interaction~ = 0.258               *P* ~interaction~ = 0.432   *P* ~interaction~ = 0.260                                                             

**Note:**

\*using Logistic Regession adjusted by sex and age.

**Abbreviations:** CON, control; AG, atrophic gastritis; GC, gastric cancer; OR, odds ratio; CI, confidence interval; Ref, reference.

Associations of SNPs with clinicopathological parameters of GC patients {#sec015}
-----------------------------------------------------------------------

Analysis of the relation of *MTOR* rs1064261 and *AKT* rs1130233 with clinicopathological parameters in GC patients suggested that the *AKT* rs1130233 GA and (GA+AA) variant genotypes occur more frequently in GC patients without lymph node metastasis than in those with lymph node metastasis (GA 89.1% vs. 71.1%, *P* = 0.012; GA+AA 92.2% vs. 81.1%, *P* = 0.030). The GA, AA, and (GA+AA) genotypes were more frequent in drinkers than in nondrinkers (GA 61.0% vs. 95.8%, *P* = 0.047; AA 63.6% vs. 88.9%, *P* = 0.047; GA+AA 76.8% vs. 96.9%, *P* = 0.038; [Table 5](#pone.0136447.t005){ref-type="table"}). However, no significant association was observed between *MTOR* rs1064261 variants and clinicopathological parameters in GC patients.

10.1371/journal.pone.0136447.t005

###### Correlation between MTOR rs1064261 or AKT rs1130233 polymorphisms and clinicopathological parameters in gastric cancer.

![](pone.0136447.t005){#pone.0136447.t005g}

  Variables               Wild   Heterozygous   *P*                                           Mutation   *P*                                           Dominance model                               Recessive model
  ----------------------- ------ -------------- --------------------------------------------- ---------- --------------------------------------------- --------------------------------------------- ---------------------------------------------
  **MTOR rs1064261**                                                                                                                                                                                 
  Age                                           0.772                                                    1.000[^a^](#t005fn002){ref-type="table-fn"}   0.845                                         1.000[^a^](#t005fn002){ref-type="table-fn"}
  ≤50                     44     10                                                           0                                                                                                      
  \>50                    124    25                                                           1                                                                                                      
  Sex                                           0.278                                                    0.325[^a^](#t005fn002){ref-type="table-fn"}   0.400                                         0.309[^a^](#t005fn002){ref-type="table-fn"}
  Male                    114    27                                                           0                                                                                                      
  Female                  54     8                                                            1                                                                                                      
  Borrmann type                                 0.814                                                    0.429[^a^](#t005fn002){ref-type="table-fn"}   0.672                                         0.432[^a^](#t005fn002){ref-type="table-fn"}
  Borrmann I--II          62     13                                                           1                                                                                                      
  Borrmann III--IV        84     16                                                           0                                                                                                      
  Lauren classification                         0.443                                                    1.000[^a^](#t005fn002){ref-type="table-fn"}   0.381                                         1.000[^a^](#t005fn002){ref-type="table-fn"}
  Intestinal              64     11                                                           0                                                                                                      
  Diffuse                 105    24                                                           1                                                                                                      
  TNM stage                                     0.855                                                    1.000[^a^](#t005fn002){ref-type="table-fn"}   0.759                                         1.000[^a^](#t005fn002){ref-type="table-fn"}
  I--II                   98     21                                                           1                                                                                                      
  III--IV                 70     14                                                           0                                                                                                      
  Growth pattern                                0.787                                                    NA                                            0.787                                         NA
  Massive and Nested      59     11                                                           0                                                                                                      
  Diffused                52     11                                                           0                                                                                                      
  Lymphatic metastasis                          0.266                                                    0.361[^a^](#t005fn002){ref-type="table-fn"}   0.196                                         0.377[^a^](#t005fn002){ref-type="table-fn"}
  Negative                60     16                                                           1                                                                                                      
  Positive                108    19                                                           0                                                                                                      
  Depth of invasion                             0.955                                                    NA                                            0.955                                         NA
  T1+T2                   36     7                                                            0                                                                                                      
  T3+T4                   75     15                                                           0                                                                                                      
  Smoking                                       0.557                                                    NA                                            0.557                                         NA
  Nonsmoker               68     12                                                           0                                                                                                      
  Smoker                  43     10                                                           0                                                                                                      
  Acohol drinking                               0.150                                                    NA                                            0.150                                         NA
  Nondrinker              78     12                                                           0                                                                                                      
  Drinker                 33     10                                                           0                                                                                                      
  Family history                                0.774[^a^](#t005fn002){ref-type="table-fn"}              NA                                            0.774[^a^](#t005fn002){ref-type="table-fn"}   NA
  No                      89     17                                                           0                                                                                                      
  Yes                     22     5                                                            0                                                                                                      
  *H*. *pylori*-IgG                             0.171                                                    0.443[^a^](#t005fn002){ref-type="table-fn"}   0.241                                         0.421[^a^](#t005fn002){ref-type="table-fn"}
  Negative                73     11                                                           1                                                                                                      
  Positive                93     24                                                           0                                                                                                      
  **AKT rs1130233**                                                                                                                                                                                  
  Age                                           0.627                                                    0.799                                         0.673                                         0.873
  ≤50                     7      30                                                           17                                                                                                     
  \>50                    23     78                                                           49                                                                                                     
  Sex                                           0.733                                                    0.209                                         0.458                                         0.156
  Male                    19     72                                                           50                                                                                                     
  Female                  11     36                                                           16                                                                                                     
  Borrmann type                                 0.960                                                    0.880                                         0.922                                         0.866
  Borrmann I--II          11     39                                                           26                                                                                                     
  Borrmann III--IV        15     52                                                           33                                                                                                     
  Lauren classification                         0.758                                                    0.594                                         0.973                                         0.262
  Intestinal              11     36                                                           28                                                                                                     
  Diffuse                 19     71                                                           38                                                                                                     
  TNM stage                                     0.912                                                    0.618                                         0.887                                         0.391
  I--I                    18     66                                                           36                                                                                                     
  III--IV                 12     42                                                           30                                                                                                     
  Growth pattern                                0.957                                                    0.624                                         0.810                                         0.497
  Massive and Nested      9      36                                                           25                                                                                                     
  Diffused                9      35                                                           19                                                                                                     
  Lymphatic metastasis                          **0.012**                                                0.183                                         **0.030**                                     0.369
  Negative                6      49                                                           22                                                                                                     
  Positive                24     59                                                           44                                                                                                     
  Depth of invasion                             0.970                                                    0.769                                         0.922                                         0.629
  T1+T2                   6      24                                                           13                                                                                                     
  T3+T4                   12     47                                                           31                                                                                                     
  Smoking                                       0.560                                                    0.578                                         0.544                                         0.861
  Nonsmoker               12     42                                                           26                                                                                                     
  Smoker                  6      29                                                           18                                                                                                     
  Alcohol drinking                              **0.047**                                                **0.047**                                     **0.038**                                     0.484
  Nondrinker              16     25                                                           28                                                                                                     
  Drinker                 2      46                                                           16                                                                                                     
  Family history                                0.083[^a^](#t005fn002){ref-type="table-fn"}              0.541[^a^](#t005fn002){ref-type="table-fn"}   0.203[^a^](#t005fn002){ref-type="table-fn"}   0.343
  No                      12     61                                                           33                                                                                                     
  Yes                     6      10                                                           11                                                                                                     
  *H*. *pylor*i-IgG                             0.973                                                    0.759                                         0.880                                         0.680
  Negative                13     46                                                           26                                                                                                     
  Positive                17     61                                                           39                                                                                                     

**Note:**

^a^, when the theoretical frequency of less than 5, using the Fisher\'s exact test; Wild, heterozygous, mutation, dominance model and recessive model of MTOR rs1064261 polymorphisms are TT, TC, CC, TC+CC vs. TT and CC vs. TC+TT, respectively. Wild, heterozygous, mutation, dominance model and recessive model of AKT rs1130233 polymorphisms are GG, GA, AA, GA+AA vs. GG, AA vs. GA+GG, respectively.

**Abbreviations:** NA, not available; T1+T2, mucosa, submucosa, muscularis propria; T3+T4, subserosa, serosa.

No association between SNPs and GC patient survival {#sec016}
---------------------------------------------------

Univariable and multivariable Cox proportional hazards models were performed to assess the effect of *MTOR* rs1064261 and *AKT* rs1130233 polymorphisms on GC survival ([Table 6](#pone.0136447.t006){ref-type="table"}). Because Lauren's classification, TNM stage, growth pattern, invasion depth, and lymph node metastasis were significantly associated with survival (*P*\<0.05, shown in [Table 3](#pone.0136447.t003){ref-type="table"}), they were considered as adjusted covariables in the Cox proportional hazards regression model. The results showed no significant association between the two SNPs and GC prognosis ([Table 6](#pone.0136447.t006){ref-type="table"}). Similarly, a stratified analysis did not demonstrate any significant association between SNP genotype and GC prognosis ([S6 Table](#pone.0136447.s006){ref-type="supplementary-material"}).

10.1371/journal.pone.0136447.t006

###### Univariable and multivariable cox proportional hazard analysis for MTOR rs1064261 and AKT rs1130233 polymorphisms.

![](pone.0136447.t006){#pone.0136447.t006g}

  Variables        All GC   Death   MST                                           Univariable   Multivariable[^b^](#t006fn003){ref-type="table-fn"}           
  ---------------- -------- ------- --------------------------------------------- ------------- ----------------------------------------------------- ------- ------------------
  MTOR rs1064261                                                                                                                                              
  TT               168      57      NA                                                          1(Ref)                                                        1(Ref)
  TC               35       10      NA                                            0.593         0.83(0.43--1.63)                                      0.224   0.52(0.18--1.49)
  CC               1        0       NA                                            0.655         0.05(0--27266.94)                                     NA      NA
  TC+CC vs. TT                                                                    0.523         0.80(0.41--1.57)                                      0.224   0.52(0.18--1.49)
  CC vs. TC+TT                                                                    0.663         0.05(0--36725.40)                                     NA      NA
  AKT rs1130233                                                                                                                                               
  GG               30       10      62.81[^a^](#t006fn002){ref-type="table-fn"}                 1(Ref)                                                        1(Ref)
  GA               108      33      59.47[^a^](#t006fn002){ref-type="table-fn"}   0.893         0.95(0.47--1.93)                                      0.517   1.44(0.48--4.35)
  AA               66       24      54.30[^a^](#t006fn002){ref-type="table-fn"}   0.790         1.11(0.53--2.31)                                      0.434   1.57(0.51--4.86)
  GA+AA vs. GG                                                                    0.991         1.00(0.51--1.97)                                      0.483   1.45(0.51--4.15)
  AA vs. GG+GA                                                                    0.546         1.17(0.71--1.92)                                      0.882   1.05(0.54--2.07)

**Note:**

^a^, mean survival time was provided when MST could not be calculated;

^b^, using multivariable COX proportional hazards model adjusted by Lauren classification, TNM stage, growth pattern, depth of invasion, lymphatic metastasis, and multivariate survival analysis was carried out by adding the SNP variable to the clinicopathological parameters with *P*\<0.05.

**Abbreviations:** MST, median survival time (months); HR, hazard rate; CI, confidence interval; Ref, reference; GC, gastric cancer; NA, not available; N, number; M, months.

SNP genotype correlates with total and phosphorylated proteins expression {#sec017}
-------------------------------------------------------------------------

The expression of total and phosphorylated MTOR and AKT proteins was analyzed in tissues from the different groups of participants ([Fig 1](#pone.0136447.g001){ref-type="fig"}). Overall, there was no significant association between the *MTOR* rs1064261 or *AKT* rs1130233 polymorphism and total or phosphorylated MTOR and AKT proteins. In the *H*. *pylori*-positive subgroup, the proportion of p-AKT-positive cells was significantly higher in the variant genotype group than in the wild-type group (*P* = 0.045; [Table 7](#pone.0136447.t007){ref-type="table"}).

10.1371/journal.pone.0136447.t007

###### The effect on the polymorphisms to its protein expression in the group of gastric cancer [\*](#t007fn002){ref-type="table-fn"}

![](pone.0136447.t007){#pone.0136447.t007g}

                            Protein Expression   *P-*value   
  ------------------------- -------------------- ----------- -----------
  **MTOR**                                                   
  MTOR rs1064261 TT         14(82.4)             9(75.0)     
  MTOR rs1064261 TC         3(17.6)              3(25.0)     0.645
  MTOR rs1064261 CC         0                    0           NA
  **Phosphoryltion MTOR**                                    
  MTOR rs1064261 TT         30(83.3)             11(73.3)    
  MTOR rs1064261 TC         6(16.7)              4(26.7)     0.126
  MTOR rs1064261 CC         0                    0           NA
  **AKT(PAN)**                                               
  AKT rs1130233 GG          1(5.9)               1(12.5)     
  AKT rs1130233 GA          8(47.1)              5(62.5)     0.475
  AKT rs1130233 AA          8(47.1)              2(25.0)     0.266
  GA+AA vs. GG                                               0.638
  AA vs. GA+GG                                               0.236
  **Phosphoryltion AKT**                                     
  AKT rs1130233 GG          8(17.0)              3(37.5)     
  AKT rs1130233 GA          23(48.9)             3(37.5)     0.311
  AKT rs1130233 AA          16(34.0)             2(25.0)     0.251
  GA+AA vs. GG                                               0.233
  AA vs. GA+GG                                               0.654
  **Male**                                                   
  MTOR                                                       
  MTOR rs1064261 TT         8(72.7)              5(71.4)     
  MTOR rs1064261 TC         3(27.3)              2(28.6)     1.000
  MTOR rs1064261 CC         0                    0           
  Phosphoryltion MTOR                                        
  MTOR rs1064261 TT         21(77.8)             4(50.0)     
  MTOR rs1064261 TC         6(22.2)              4(50.0)     0.186
  MTOR rs1064261 CC         0                    0           
  AKT(PAN)                                                   
  AKT rs1130233 GG          1(8.3)               1(16.7)     
  AKT rs1130233 GA          4(33.3)              4(66.7)     0.282
  AKT rs1130233 AA          7(58.3)              1(16.7)     
  Phosphoryltion AKT                                         
  AKT rs1130233 GG          5(16.7)              2(40.0)     
  AKT rs1130233 GA          15(50.0)             2(40.0)     0.562
  AKT rs1130233 AA          10(33.3)             1(20.0)     
  **Female**                                                 
  MTOR                                                       
  MTOR rs1064261 TT         6(100.0)             4(80.0)     
  MTOR rs1064261 TC         0                    1(20.0)     0.455
  MTOR rs1064261 CC         0                    0           
  Phosphoryltion MTOR                                        
  MTOR rs1064261 TT         9                    7           
  MTOR rs1064261 TC         0                    0           NA
  MTOR rs1064261 CC         0                    0           
  AKT(PAN)                                                   
  AKT rs1130233 GG          0                    0           
  AKT rs1130233 GA          4(80.0)              1(50.0)     
  AKT rs1130233 AA          1(20.0)              1(50.0)     1.000
  Phosphoryltion AKT                                         
  AKT rs1130233 GG          3(17.6)              1(33.3)     
  AKT rs1130233 GA          8(47.1)              1(33.3)     1.000
  AKT rs1130233 AA          6(35.3)              1(33.3)     
  **H.pylori (+)**                                           
  MTOR                                                       
  MTOR rs1064261 TT         2(66.7)              3(75.0)     
  MTOR rs1064261 TC         1(33.3)              1(25.0)     1.000
  MTOR rs1064261 CC         0                    0           
  Phosphoryltion MTOR                                        
  MTOR rs1064261 TT         14(82.4)             4(66.7)     
  MTOR rs1064261 TC         3(17.6)              2(33.3)     0.576
  MTOR rs1064261 CC         0                    0           
  AKT(PAN)                                                   
  AKT rs1130233 GG          0                    1(20.0)     
  AKT rs1130233 GA          3(42.9)              3(60.0)     0.369
  AKT rs1130233 AA          4(57.1)              1(20.0)     
  Phosphoryltion AKT                                         
  AKT rs1130233 GG          2(66.7)              2(11.1)     
  AKT rs1130233 GA          0                    11(61.1)    **0.045**
  AKT rs1130233 AA          1(33.3)              5(27.8)     
  **H.pylori (-)**                                           
  MTOR                                                       
  MTOR rs1064261 TT         7(77.8)              11(84.6)    
  MTOR rs1064261 TC         2(22.2)              2(15.4)     1.000
  MTOR rs1064261 CC         0                    0           
  Phosphoryltion MTOR                                        
  MTOR rs1064261 TT         16(84.2)             7(77.8)     
  MTOR rs1064261 TC         3(15.8)              2(22.2)     1.000
  MTOR rs1064261 CC         0                    0           
  AKT(PAN)                                                   
  AKT rs1130233 GG          1(10.0)              0           
  AKT rs1130233 GA          5(50.0)              2(66.7)     1.000
  AKT rs1130233 AA          4(40.0)              1(33.3)     
  Phosphoryltion AKT                                         
  AKT rs1130233 GG          1(20.0)              6(20.7)     
  AKT rs1130233 GA          3(60.0)              12(41.4)    0.826
  AKT rs1130233 AA          1(20.0)              11(37.9)    

**Note:**

\*using Logistic Regession adjusted by sex, age and *H*.*pylori* infection status.

![The expression of mTOR and AKT protein in tissue in situ.\
A. the expression of mTOR protein in gastric cancer mucosa (100×); B. the expression of p-mTOR protein in gastric mucosa (100×); C. the expression of AKT protein in gastric cancer mucosa (100×); D. the expression of p-AKT protein in gastric mucosa (100×).](pone.0136447.g001){#pone.0136447.g001}

Discussion {#sec018}
==========

In this study, we report for the first time an association of the *MTOR* rs1064261 and *AKT* rs1130233 polymorphisms with GC risk and prognosis. In males, the *MTOR* rs1064261 (TC+CC) genotype and the A allele of *AKT* rs1130233 were associated with an increased GC risk. In *H*. *pylori*-negative males, the *AKT* rs1130233 (GA+AA) genotype was associated with an increased AG risk. In addition, the *AKT* rs1130233 (GA+AA) genotype showed a significant interaction with *H*. *pylori* infection in CON→AG→GC progression. The variant genotype of *AKT* rs1130233 was associated with increased p-AKT protein expression. The *AKT* rs1130233 polymorphism was also associated with lymph node metastasis and alcohol drinking. These findings provide experimental evidence to support MTOR and AKT as potential biomarkers of specific types of GC and also provide clues to the interaction between *H*. *pylori* infection and MTOR/AKT signaling.

The *MTOR* gene is located on human chromosome 1p36.2 and encodes the 289 kDa MTOR protein, consisting of 2549 amino acids. MTOR is a member of phosphatidyl inositol kinase (PIK) family and has serine/threonine kinase activities. We found that the *MTOR* gene (TC+CC) variant genotype was associated with an increased GC risk in males, suggesting that it is involved in carcinogenesis. MTOR mainly exists in the cytoplasm under normal conditions and enters the nucleus after activation to regulate the downstream targets eukaryotic initiation factor 4E (eIF-4E) binding protein 1 (4E-BP1) and ribosome 40S small subunit S6 protein kinase (p70S6K) \[[@pone.0136447.ref022]--[@pone.0136447.ref024]\]. The latter is an essential member of the PI3K/AKT/MTOR pathway and a central metabolic signaling molecule. MTOR integrates a variety of cellular signals from growth factors and nutritional and energy status; thus, it has important biological functions in angiogenesis and cell growth, proliferation, metabolism, migration, differentiation, and apoptosis \[[@pone.0136447.ref025]\]. Its function is closely linked to the transformation of normal to cancer cells and to cancer cell proliferation. Genetic variations in genes of the MTOR signaling pathway (*PI3K*, *AKT*, and *PTEN*) can promote carcinogenesis \[[@pone.0136447.ref026]--[@pone.0136447.ref028]\]. *MTOR* SNPs are reported to be associated with susceptibility to GC \[[@pone.0136447.ref007], [@pone.0136447.ref009]\], renal cell carcinoma \[[@pone.0136447.ref006]\], prostate cancer \[[@pone.0136447.ref008]\], and esophageal squamous cancer \[[@pone.0136447.ref010]\]. These SNPs might affect the levels of MTOR expression and transcriptional activity, thereby altering the protein function. The G allele of *MTOR* rs2295080 polymorphism is associated with a reduced GC risk, possibly resulting from reduced promoter activity and mRNA expression \[[@pone.0136447.ref007]\]. Another *MTOR* polymorphism located in the promoter region, rs1883965 G→A, confers increased risks of GC \[[@pone.0136447.ref009]\] and esophageal squamous cancer \[[@pone.0136447.ref010]\]. Our findings suggest that the (TC+CC) genotype is associated with an increased GC risk in males, although no effect on protein expression was observed. *MTOR* can promote cell proliferation and somewhat "oncogenic" characteristics. The variant genotype might have even more oncogenic activity. As men are more likely to be exposed to multiple risk exposure factors (smoking, drinking and unhealthy living habits), carriers of certain genotype may be susceptible to an increased risk of GC.

*AKT*, the v-*AKT* murine thymoma viral oncogene homolog, maps to human chromosome 14q32.32 and encodes a 56 kda protein, consisting of 480 amino acids \[[@pone.0136447.ref015]\]. AKT is an important effector of the PI3K/AKT/MTOR signal pathway, and genetic mutation or abnormal protein expression can alter a variety of cellular process including migration, proliferation, growth, and survival. Additionally, AKT activation is involved in cell proliferation and apoptosis, which are related to cancer initiation and progression \[[@pone.0136447.ref029]\]. *AKT* SNPs are reported to be associated with susceptibility to and/or the prognosis of various cancer types including nasopharyngeal carcinoma \[[@pone.0136447.ref012]\], oral squamous cell carcinoma \[[@pone.0136447.ref013], [@pone.0136447.ref030]\], non-small cell lung cancer \[[@pone.0136447.ref014], [@pone.0136447.ref015]\], pancreatic ductal adenocarcinoma \[[@pone.0136447.ref031]\], and GC \[[@pone.0136447.ref032]\] via effects on protein expression and transcriptional activity. Wang et al. studied four SNPs including rs1130233 in a Chinese population \[[@pone.0136447.ref013]\], and found that three polymorphisms were associated with susceptibility to oral squamous cell carcinoma or DFS, but with no significant relation for rs1130233. Zhang et al. reported that AA haplotypes of *AKT* rs1130233 and rs2494732 conferred an increased nasopharyngeal carcinoma risk \[[@pone.0136447.ref012]\] and that some *AKT* haplotypes cause increased AKT protein expression \[[@pone.0136447.ref033], [@pone.0136447.ref034]\], leading to altered cellular migration and proliferation. Therefore, the *AKT* rs1130233 A allele might have increased proliferative activity. In this study, we found that the *AKT* rs1130233 A allele conferred an increased risk of GC in males. Generally, males have a higher GC incidence and a higher GC mortality rate than adult women \[[@pone.0136447.ref035]\]. The high level of exposure of males to environmental risk factors (smoking, drinking and unhealthy living habits) increases their susceptibility to GC \[[@pone.0136447.ref036]\]. As the A allele might have stronger proliferative activity, the combined effect of *AKT* polymorphism and gender could partially explain the observed high GC risk associated with the *AKT* rs1130233 polymorphism in males.

In addition, we found that in the *H*. *pylori*-negative subgroup, the *AKT* rs1130233 (GA+AA) genotype was associated with increased AG risk. The *AKT* rs1130233 polymorphism showed a significant interaction with *H*. *pylori* infection in CON→AG→GC progression. It is widely accepted that *H*. *pylori* is a major cause of GC. *H*. *pylori* virulent factors may induce abnormal cell proliferation and apoptosis through regulating signaling pathways (including PI3K/AKT); this is a recent research hotspot \[[@pone.0136447.ref037]--[@pone.0136447.ref039]\]. Tabassam et al. suggested that the AKT phosphorylation induced by the *H*. *pylori* virulence factors cag PAI and OipA regulates intracellular signals responsible for a series of cellular functions involved in gastric carcinogenesis. The specific promotion of AKT serine 473 or threonine 308 phosphorylation by cag PAI and OipA may disrupt downstream proliferation and apoptosis signals. A combination of cag PAI and OipA is sufficient to activate the PI3K/PDK1 pathway and AKT/ERK/ downstream signaling \[[@pone.0136447.ref039]\]. Nakayama et al. reported that *H*. *pylori* virulence factor VacA induces β-catenin function by activating the PI3K/AKT pathway and inactivating GSK33β \[[@pone.0136447.ref038]\], thus regulating cell proliferation, differentiation and apoptosis. These data suggest that the interaction of *H*. *pylori* with activated AKT has a biological function. However, neither of the two SNPs included in this study nor *H*. *pylori* infection in the context of these SNPs showed a significant interaction with GC. Overall, these data emphasize the important role of the *AKT* rs1130233 polymorphism in the PI3K/MTOR/AKT pathway. In addition, in the *H*. *pylori*-positive subgroup, those with the *AKT* rs1130233 variant genotype had increased p-AKT expression. As this polymorphism showed an interaction with *H*. *pylori* infection, the effect of this polymorphism on protein expression may only emerge in the presence of *H*. *pylori* infection. A genetic mutation leading to abnormal AKT expression is reported to promote cell migration and proliferation \[[@pone.0136447.ref040], [@pone.0136447.ref041]\], which might explain why this polymorphism increased the risk of AG. Future large-scale studies are required to confirm these results.

We also compared the genotype distribution of these two polymorphisms in groups with different clinicopathological parameters and assessed their relation with GC prognosis. We found that the *AKT* rs1130233 GA, AA, and (GA+AA) genotypes were more frequent in drinkers than in nondrinkers. We therefore assume that drinkers with *AKT* rs1130233 GA, AA, and (GA+AA) genotypes are more susceptible to GC. Avan et al. \[[@pone.0136447.ref031]\] reported that the *AKT* rs1130233 A allele is associated with reduced survival of pancreatic ductal adenocarcinoma patients, which might be attributed to reduced *AKT1* mRNA and protein expression and reduced apoptosis efficiency \[[@pone.0136447.ref033], [@pone.0136447.ref042]\]. The *AKT* rs1130233 A allele is a risk genotype for cancer, possibly in association with alcohol drinking as consuming alcohol was one of the increased risk factors of GC\[[@pone.0136447.ref043]--[@pone.0136447.ref046]\]. However, no significant association of these two SNPs with GC survival was found by Cox regression analysis. Due to the relatively small sample size, the recall bias might exist in the case-control study, and outcome status may have caused cases to alter their exposure profile. Therefore, further experiments and large-scale studies were needed to confirm our results.

The present study has some limitations. First, the sample size was relatively small, especially for survival and protein expression analyses, both of which need further confirmation in large populations. Second, only OS was analyzed in the survival analysis and other prognostic parameters such as progression-free survival are also warranted. Third, the survival analysis was only performed in a subset of the whole GC patients which could make the probability of a selective bias, and a large sample size for the prognostic study should be performed in the near future. Fourth, functional experiments are required to elucidate the underlying disease mechanism.

Conclusion {#sec019}
==========

In summary, the relation of *MTOR* rs1064261 and *AKT* rs1130233 polymorphisms with GC susceptibility and OS has been shown for the first time. *MTOR* rs1064261 and *AKT* rs1130233 polymorphisms were significantly associated with GC risk in males. The *AKT* rs1130233 polymorphism and *H*. *pylori* infection showed a significant interaction in CON→AG→GC progression. The *AKT* rs1130233 polymorphism was associated with increased p-AKT protein expression in *H*. *pylori*-positive individuals. The *AKT* rs1130233 polymorphism was associated with variations in clinicopathological parameters including lymph node metastasis and alcohol drinking. Future large-scale investigations and functional studies are needed to confirm these results.
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